No matches

28 search results for: biomarkers

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation
Pulmonology
Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation
interactivity

Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.

View more
Exploring the Potential Disease-Modifying Approaches in AD
Dermatology
Exploring the Potential Disease-Modifying Approaches in AD
interactivity

Explore the concept of disease modification in atopic dermatitis through this interactive infographic, which highlights potential considerations such as optimal sustained disease control, subclinical inflammation, the pathophysiology of AD, and atopic/non-atopic comorbidities.

View more
Why Is It Important to Assess Lung Function in Pediatric Asthma?
Pulmonology
Why Is It Important to Assess Lung Function in Pediatric Asthma?
interactivity

Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma.

View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: PanamaChange country/region